The Series B round was led by Intel’s investment arm, and also included Sony’s corporate venture capital arm, Nautilus Venture Partners, Applied Ventures, Bold Capital and more. Exo has now raised nearly $50 million since its 2015 founding; the new investment will go toward expanding the company’s engineering, sales and operations teams and advancing the ultrasound device’s progress toward FDA clearance, according to co-founder and CEO Sandeep Akkaraju.
Exo’s platform relies on advanced AI, nanomaterial, novel sensor and other technologies to achieve high-quality image fidelity, penetration depth and 3D imaging that can fit in the palm of a clinician’s hand, but is significantly more affordable than comparable imaging equipment.
More articles on health IT:
7 secrets to being successful in blockchain
How Reliant Medical Group reduced EHR burnout with 3 steps
OSF Healthcare’s CIO: 4 unconventional characteristics to a successful IT team
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
